Article Contents ::
- 1 The Brand Name NIMODIP Has Generic Salt :: Nimodipine
- 2 NIMODIP Is From Company U S V Priced :: Rs. 91.82
- 3 NIMODIP have Nimodipine is comes under Sub class Anti Hypertensives of Main Class Cardiovascular System
- 4 Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Hypertensives
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name NIMODIP Has Generic Salt :: Nimodipine
NIMODIP Is From Company U S V Priced :: Rs. 91.82
NIMODIP have Nimodipine is comes under Sub class Anti Hypertensives of Main Class Cardiovascular System
Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Hypertensives
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Nimodipine | TAB | Rs. 91.82 | 10 |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 10 |
| NIMODIP | U S V | 30MG | 10 | Rs. 91.82 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From U S V :: NIMODIP | Nimodipine | Cardiovascular System | Anti Hypertensives |
Indications for Drugs ::
Subarachnoid haemorrhage, Stroke prevention
Drug Dose ::
Adult: PO Prophylaxis of neurological deficit following subarachnoid haemorrhage 60 mg 4 hrly for 21 days beginning w/in 4 days of onset of haemorrhage. IV Ischaemic neurological deficits following subarachnoid haemorrhage Initial: 1 mg/hr for 2 hr, up to 2 mg/hr if no severe decrease in BP is observed. Start treatment at once and continue for 5-14 days. Total duration should not exceed 21 days if patient has received oral treatment.
Contraindication ::
0
Drug Precautions ::
Cerebral oedema, severely raised intracranial pressure, idiopathic hypertrophic subaortic stenosis (IHSS), elderly, severe liver disease. Inadvertent IV admin of the contents of capsules has resulted in CV collapse, hypotension, bradycardia and death. Tablets should not be administered concomitantly with IV solution.
Drug Side Effects ::
Peripheral oedema, hypotension, palpitations, tachycardia, flushing, dizziness, headache, nausea, increased micturition frequency, lethargy, eye pain, mental depression, visual disturbances, gingival hyperplasia, myalgia, tremor, impotence, fever, paradoxical increase in ischaemic chest pain during initiation of treatment, rashes, abnormalities in liver function (including cholestasis), GI obstruction in some tablets covered in indigestable membrane. Potentially Fatal: Angina/MI, symptomatic hypotension.
Pregnancy category ::
3
Drug Mode of Action ::
Nimodipine inhibits inflow of Ca ions into cells by blocking Ca channels or select voltage-sensitive areas resulting in relaxation of vascular smooth muscle and myocardium during depolarisation. Nimodipine has greater action on the cerebral vessels because of its high lipophilicity.
Drug Interactions ::
Plasma concentration and efficacy may be significantly reduced when administered w/ strong CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin). May increase serum levels and toxicity of phenytoin. Increased plasma concentrations w/ cimetidine or sodium valproate. Potentially Fatal: Increased risk of significant hypotension w/ concomitant potent CYP3A4 inhibitors (e.g. clarithromycin, ritonavir, ketoconazole, nefazodone).
